Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 31 for:    CTPS1

Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00674895
Recruitment Status : Unknown
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
First Posted : May 8, 2008
Last Update Posted : January 5, 2009
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.

Brief Summary:
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Phase 1

Detailed Description:

Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement. The primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. PD is both chronic and progressive.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have PD.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control and Treatment of Parkinson's Disease.
Study Start Date : May 2008
Estimated Primary Completion Date : May 2010
Estimated Study Completion Date : June 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation




Primary Outcome Measures :
  1. Cure for PD [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Rehabilitation of PD Patients [ Time Frame: 2 Years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • People with Parkinson's Disease

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674895


Locations
Layout table for location information
Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Investigators
Layout table for investigator information
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.

Layout table for additonal information
Responsible Party: Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier: NCT00674895     History of Changes
Other Study ID Numbers: GAAD-PD-CTP1
First Posted: May 8, 2008    Key Record Dates
Last Update Posted: January 5, 2009
Last Verified: January 2009
Keywords provided by GAAD Medical Research Institute Inc.:
Idiopathic Parkinson's Disease
Lewy Body Parkinson's Disease
Paralysis Agitans
Parkinson's Disease, Idiopathic
Parkinson's Disease, Lewy Body
Primary Parkinsonism
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases